Affinage

SS18

Protein SSXT · UniProt Q15532

Length
418 aa
Mass
45.9 kDa
Annotated
2026-06-10
100 papers in source corpus 27 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SS18 is a BAF-subtype-specific subunit of mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes, co-purifying exclusively with ARID1A/ARID1B-containing BAF (not PBAF) complexes (PMID:22442726). It nucleates BAF assembly through two complementary modules: its N-terminal ~70 residues mediate direct interaction with the complex, while its C-terminal intrinsically disordered QPGY domain, rich in tyrosines, drives liquid-liquid phase separation that recruits the BRG1 ATPase into nuclear condensates (PMID:35585082, PMID:34215745); structurally, SS18 contacts BRG1 through a heterodimer interface, and both phase separation and BAF assembly are required for function (PMID:35585082). SS18 incorporation into BAF is developmentally regulated—it is exchanged for CREST at mitotic exit to form neuron-specific nBAF complexes, and SS18 loss in neural stem cells causes cell-cycle exit and self-renewal failure (PMID:23785148); germline disruption of Ss18 in mice causes embryonic lethality from placental vascular failure (PMID:16926188). The recurrent oncogenic SS18-SSX fusion subverts this biology: it competes with wild-type SS18 for BAF incorporation to form an altered complex lacking the tumor suppressor BAF47/SMARCB1 and drives whole-complex degradation of canonical BAF (PMID:23540691, PMID:34078620). The fusion globally retargets residual BAF complexes from enhancers to polycomb-repressed bivalent domains, opposing PRC2 and activating developmental genes such as Sox2, in part through physical association with the KDM2B-PRC1.1 complex on unmethylated CpG islands (PMID:23540691, PMID:29861296, PMID:29502955). SS18-SSX additionally represses target genes by bridging ATF2 and TLE1/Groucho, silencing anti-apoptotic MCL1 and BCL2A1 (PMID:22439931, PMID:22797074), and engages TCF/LEF-TLE-HDAC complexes to activate Wnt targets independent of β-catenin (PMID:26905812). The fusion can also activate transcription independently of BAF ATPase activity by recruiting the histone acetyltransferase EP300 via the QPGY domain (PMID:41659547). Its chromatin occupancy is reinforced by WDR5-promoted H3K4 methylation and by SUMOylation of cBAF subunits, and is sustained by oncogenic engagement of YAP/TAZ-TEAD signaling and HDM2-mediated p53 destabilization (PMID:18234968, PMID:40267190, PMID:41193430, PMID:30814111, PMID:40804185).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2006 High

    Established that SS18 has an essential physiological role in development, answering whether the gene matters in vivo beyond its known fusion in sarcoma.

    Evidence Targeted Ss18 gene disruption in mice with placental histology and expression profiling

    PMID:16926188

    Open questions at the time
    • Molecular mechanism linking SS18 loss to vascular/chorio-allantoic failure not resolved
    • Relationship of placental phenotype to BAF chromatin remodeling not established
  2. 2012 High

    Defined SS18 as a BAF-restricted (not PBAF) mSWI/SNF subunit, fixing its position in the chromatin remodeling machinery.

    Evidence Tandem affinity purification/mass spectrometry with complex walking in human cells

    PMID:22442726

    Open questions at the time
    • Did not define which SS18 domains mediate BAF specificity
    • Functional contribution of SS18 to remodeling activity not assayed
  3. 2012 High

    Showed the oncogenic fusion acts as a repressive transcription factor scaffold, bridging ATF2 and TLE1 to silence target genes—an early mechanism for fusion-driven gene repression.

    Evidence Affinity purification/MS, reciprocal Co-IP, siRNA knockdown and expression profiling in SS cell lines

    PMID:22439931 PMID:22797074

    Open questions at the time
    • Relationship between this repressive complex and BAF incorporation not integrated
    • Genome-wide scope of ATF2/TLE1-mediated repression not mapped
  4. 2013 High

    Demonstrated the core oncogenic mechanism: SS18-SSX competes with wild-type SS18 for BAF assembly, evicts BAF47/SMARCB1, and reverses polycomb repression at Sox2.

    Evidence Reciprocal Co-IP, ChIP-seq, RNAi, and overexpression rescue in synovial sarcoma cell lines

    PMID:23540691

    Open questions at the time
    • Genome-wide retargeting pattern not yet established
    • Mechanism by which the altered complex evades polycomb not defined
  5. 2013 High

    Revealed developmentally programmed SS18 subunit exchange (SS18→CREST forming nBAF), establishing SS18 as a regulator of neural stem cell self-renewal and differentiation.

    Evidence Proteomic BAF composition analysis and SS18 knockdown in neural stem cells and neurons

    PMID:23785148

    Open questions at the time
    • Signal triggering the SS18/CREST switch not identified
    • Connection to phase-separation behavior of SS18 not addressed
  6. 2018 High

    Mapped the genome-wide consequence of the fusion: global redistribution of BAF from enhancers to broad polycomb domains, and engagement of KDM2B-PRC1.1, explaining bivalent developmental gene activation.

    Evidence ChIP-seq, ATAC-seq, RNA-seq, Co-IP, and KDM2B knockdown in primary tumors and SS cell lines

    PMID:29502955 PMID:29861296

    Open questions at the time
    • BAF47 reassembly shown dispensable for proliferative arrest, leaving the relevant effector unclear
    • How residual BAF is physically retargeted to polycomb loci not fully resolved
  7. 2021 High

    Showed the fusion drives degradation of the entire canonical BAF complex rather than selective subunit loss, reframing the basis of SMARCB1 reduction in synovial sarcoma.

    Evidence Mouse genetics, recombinant CBAF reconstitution, and quantitative proteomics of BAF subtypes

    PMID:34078620

    Open questions at the time
    • Degradation machinery targeting CBAF not identified
    • Why PBAF/GBAF are spared not mechanistically explained
  8. 2021 High

    Established phase separation as the assembly principle: SS18's tyrosine-rich C-terminal IDR forms condensates while the N-terminal 70 aa engages BAF, both required for the pluripotent-to-somatic transition.

    Evidence CRISPR whole-genome screen, domain-mutant rescue, live-cell condensate imaging, and BAF Co-IP

    PMID:34215745

    Open questions at the time
    • Quantitative contribution of condensation versus direct binding to remodeling not separated
    • In vivo relevance of condensates to endogenous BAF function not established
  9. 2022 High

    Provided the structural and biophysical basis for SS18-BRG1 assembly, showing a defined heterodimer interface and tyrosine-driven LLPS that recruits BRG1, both required for transformation.

    Evidence Crystal structures of SS18/BRG1 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, and NIH3T3 transformation

    PMID:35585082

    Open questions at the time
    • Structure of the full SS18-containing BAF assembly not determined
    • How SS18-SSX alters condensate composition not addressed here
  10. 2024 Medium

    Linked condensate behavior to the fusion's targeting specificity: SS18-SSX condensates read H2AK119ub via the SSX moiety and hijack wild-type SS18 condensates to silence tumor suppressors.

    Evidence Small-molecule screening, mutant assays, live-cell condensate imaging, and histone-mark ChIP

    PMID:39468035

    Open questions at the time
    • Single study without independent replication
    • Direct biophysical demonstration of H2AK119ub recognition by SSX not shown
  11. 2025 Medium

    Identified a BAF-ATPase-independent activation arm in which SS18-SSX recruits EP300 through the QPGY domain, separating fusion oncogenic transcription from remodeling activity.

    Evidence Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumors, domain mutants, and EP300 Co-IP (preprint)

    PMID:41659547

    Open questions at the time
    • Preprint not yet peer-reviewed
    • Relative contribution of EP300 versus BAF-dependent activity to tumor maintenance not quantified
  12. 2025 Medium

    Uncovered cofactor and post-translational dependencies (WDR5-driven H3K4 methylation; SUMOylation) that sustain SS18-SSX chromatin occupancy, nominating druggable nodes.

    Evidence Co-IP, ChIP-seq, CRISPR screens, and pharmacologic degradation/inhibition (WDR5 PROTAC, TAK-981) with in vivo validation

    PMID:40267190 PMID:40804185 PMID:41193430

    Open questions at the time
    • Direct versus indirect routes by which SUMOylation stabilizes fusion occupancy not fully separated
    • Whether these dependencies are specific to the fusion or shared with wild-type SS18 unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How wild-type SS18 condensation and BAF assembly are physiologically regulated across tissues, and how the fusion's multiple parallel mechanisms (BAF retargeting, EP300 recruitment, ATF2/TLE repression, YAP/TAZ and p53 axes) are integrated into a single transforming program, remains unresolved.
  • No unified hierarchy ranking the fusion's mechanistic arms
  • Cytosolic/actin-associated roles of SS18 (idx 15) not reconciled with nuclear BAF function
  • Regulation of endogenous SS18 condensate dynamics in normal development not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0005198 structural molecule activity 2 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 3 GO:0005654 nucleoplasm 2 GO:0005829 cytosol 1 GO:0005856 cytoskeleton 1
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1266738 Developmental Biology 2 R-HSA-1643685 Disease 2
Partners
ARID1AATF2EP300KDM2BSMARCA4TCF/LEFTLE1WDR5
Complex memberships
ATF2-TLE1 repressor complexBAF (canonical mSWI/SNF)KDM2B-PRC1.1nBAF (neuron-specific BAF)

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 SS18-SSX fusion protein competes with wild-type SS18 for assembly into BAF (mSWI/SNF) complexes, forming an altered complex that lacks the tumor suppressor BAF47 (hSNF5/SMARCB1). The altered SS18-SSX-containing BAF complex binds the Sox2 locus and reverses polycomb-mediated repression, activating Sox2 expression. Restoring wild-type SS18 concentration reassembles wild-type BAF complexes, retargets them away from the Sox2 locus, and restores polycomb repression of Sox2. Co-immunoprecipitation, ChIP-seq, RNAi knockdown, overexpression rescue experiments in SS cell lines Cell High 23540691
2018 SS18-SSX globally retargets BAF complexes from enhancers to broad polycomb domains genome-wide, opposing PRC2-mediated repression and activating bivalent developmental genes. Upon SS18-SSX suppression, BAF47 reassembly restores enhancer activation, but BAF47 reassembly is not required for proliferative arrest. ChIP-seq, ATAC-seq, RNA-seq in primary SS tumors and cell lines with SS18-SSX knockdown/restoration Cancer cell High 29861296
2012 SS18-SSX fusion protein forms a core complex bridging activating transcription factor 2 (ATF2) and transducin-like enhancer of split 1 (TLE1), resulting in repression of ATF2 target genes. siRNA knockdown of ATF2 or TLE1 rescues target gene expression and leads to growth suppression and apoptosis. Affinity purification/mass spectrometry of SS18-SSX complex, Co-IP, siRNA knockdown, gene expression profiling Cancer cell High 22439931
2012 SS18 is a subunit specific to BAF-type (not PBAF-type) SWI/SNF complexes in human cells, co-purifying exclusively with ARID1A/BAF250a or ARID1B/BAF250b-containing complexes. Additional BAF-specific subunits identified by tandem affinity purification include SS18L1, DPF1, DPF2, DPF3, BRD9, BCL7A, BCL7B, and BCL7C. Tandem affinity purification followed by mass spectrometry (TAP-MS) in human cells PloS one High 22442726
2013 During neuronal development, SS18 is removed from BAF complexes and replaced by CREST at mitotic exit to form neuron-specific nBAF complexes. Knockdown of SS18 in neural stem cells causes cell-cycle exit and failure to self-renew, whereas continued SS18 expression in neurons blocks dendritic outgrowth. Proteomic analysis of BAF complex composition, kinetic assembly assays, SS18 knockdown in neural stem cells and neurons, differentiation of mouse ESCs and human fibroblasts to neurons The Journal of neuroscience High 23785148
2018 SS18-SSX1 physically interacts with KDM2B-PRC1.1 (a non-canonical polycomb repressive complex 1) and co-associates with both SWI/SNF and KDM2B complexes on unmethylated CpG islands. Via KDM2B, SS18-SSX1 aberrantly activates developmentally regulated polycomb target genes; KDM2B depletion restores repression and induces irreversible mesenchymal differentiation. Co-IP, ChIP-seq, functional genomics screen, KDM2B knockdown in SS cell lines Cancer cell High 29502955
2022 SS18 assembles with BRG1 through a heterodimer interface structurally homologous to yeast SNF11/SNF2, suggesting SNF11 is a yeast homologue of SS18. The intrinsically disordered QPGY domain of SS18 undergoes liquid-liquid phase separation (LLPS) driven by tyrosine residues, and this phase separation recruits BRG1 into condensates. Both LLPS and BAF complex assembly are required for SS18-SSX oncogenic transformation of NIH3T3 cells. Crystal structure of SS18/BRG1 and SNF11/SNF2 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, NIH3T3 transformation assay Nature communications High 35585082
2021 SS18-SSX expression in mouse mesenchyme leads to whole-complex degradation of canonical BAF (CBAF), with relative increases in PBAF and GBAF complex abundance. SMARCB1 is incorporated into both PBAF and CBAF complexes in the presence of SS18-SSX, and recombinant CBAF reconstitution shows equal SMARCB1 regardless of SS18 vs SS18-SSX inclusion, indicating the reduced SMARCB1 protein levels in synovial sarcoma derive from degradation of the whole CBAF complex driven by SS18-SSX. Genetic mouse models, recombinant CBAF reconstitution in human cells, quantitative proteomics of BAF complex subtypes, ChIP-seq Cancer discovery High 34078620
2021 SS18 forms condensates in nuclei through a C-terminal intrinsically disordered region (IDR) rich in tyrosine residues. The IDR alone is insufficient to rescue the SS18-knockout pluripotent-to-somatic transition (PST) defect; the N-terminal 70 aa are additionally required for PST by interacting with the BAF complex. SS18 mediates BAF assembly through phase separation to regulate PST. CRISPR whole-genome screen, knockout rescue experiments with domain mutants, live-cell imaging of condensates, BAF complex Co-IP Nature communications High 34215745
2008 SS18-SSX directly binds the EGR1 promoter and represses EGR1 expression. This SS18-SSX occupancy correlates with trimethylation of histone H3 Lys27 (H3K27me3) and recruitment of polycomb group proteins to the EGR1 promoter. HDAC inhibitor romidepsin reverts these chromatin modifications and reactivates EGR1. Chromatin immunoprecipitation (ChIP), histone modification analysis, romidepsin treatment in SS cell lines Cancer research Medium 18519690
2006 SS18-SSX2 expression affects histone modifications at the CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region, demonstrating epigenetic gene regulation by the fusion protein. Conditional SS18-SSX2 expression, cDNA microarray, chromatin immunoprecipitation, bisulfite sequencing for DNA methylation Cancer research Medium 17018603
2008 SS18-SSX1 promotes p53 ubiquitination and degradation by stabilizing HDM2 through inhibition of HDM2 autoubiquitination, thereby negatively regulating p53 tumor-suppressive function. Overexpression and co-IP assays, ubiquitination assays, p53 stability/degradation assays in cell lines Molecular cancer research Medium 18234968
2012 SS18-SSX represses MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho. This direct transcriptional suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263. ChIP at MCL1/BCL2A1 promoters, ATF2/TLE1 Co-IP, luciferase reporter assay, ABT-263 treatment in mouse and human SS cells and in vivo mouse model Oncogene Medium 22797074
2016 SS18-SSX interacts with TCF/LEF and TLE and HDAC but not with β-catenin in vivo, and induces Wnt target gene (AXIN2) expression by forming a promoter-bound complex containing TCF/LEF and HDAC, independent of β-catenin. Co-immunoprecipitation in vivo, ChIP at AXIN2 promoter, luciferase reporter assays Scientific reports Medium 26905812
2006 Disruption of the mouse Ss18 gene causes recessive embryonic lethality due to placental failure (impaired vascularization and/or chorio-allantoic fusion). Expression profiling of knockout embryos revealed altered expression of PPARBP (peroxisome proliferator-activated receptor-binding protein), suggesting functional co-linearity between SS18, p300, and PPARBP in placental development. Targeted gene disruption in mice (knockout), placental histology, expression profiling of knockout embryos, interbreeding with Ss18l1 mutants Human molecular genetics High 16926188
2009 SS18 (SYT) isoforms localize not only to the nucleus but also to the cytosol, where they associate with actin filaments and actin-associated proteins. RNAi ablation of SS18 isoforms impairs formation of stress fibers and focal adhesions and markedly reduces cell adhesion and spreading on fibronectin and laminin-111 but not on collagen types I or IV. Isoform-specific antibody staining, co-immunoprecipitation with actin, co-sedimentation assay, co-localization by fluorescence microscopy, RNAi knockdown with adhesion assays PloS one Medium 19649286
2008 The QPGY domain (carboxy half) of SS18 (SYT) is required for cyst growth in 3D MDCK cultures, while the amino-terminal region exerts a regulatory effect. SS18 facilitates ATP release into the extracellular space of polarized MDCK cells, activating purinergic P2Y receptor signaling to drive cystogenesis. 3D collagen culture cystogenesis assay with domain-deletion mutants, ATP release measurement, P2Y receptor inhibition Experimental cell research Low 18835266
2013 SS18-SSX fusion protein displays a characteristic speckle pattern in the nucleus. Co-expression with a truncated SSX moiety (tSSX) shifts SS18-SSX localization from the speckle pattern to a diffuse pattern, suppresses cell proliferation, and reduces colony formation in synovial sarcoma cells. Fluorescence microscopy with tagged fusion proteins, co-transfection, proliferation and colony formation assays in SYO-1 and YaFuSS cells PloS one Low 24130893
2025 WDR5 (a factor for H3K4 methylation) interacts with SS18-SSX and co-localizes with it at oncogene loci, where WDR5 promotes H3K4 methylation and chromatin association of SS18-SSX-containing chromatin-remodeling complexes. Pharmacologic PROTAC-mediated degradation of WDR5 suppresses SS18-SSX oncogenic programs and additionally causes ribosomal protein deregulation leading to p53 activation, suppressing SS growth in vitro and in vivo. Co-IP of WDR5 and SS18-SSX, ChIP-seq, PROTAC degradation, genomic profiling, in vitro and xenograft in vivo assays Science advances Medium 40267190
2025 SS18-SSX activates the SUMOylation program. The SUMOylation inhibitor TAK-981 de-SUMOylates the cBAF subunit SMARCE1, stabilizing cBAF on chromatin and shifting cells away from SS18-SSX-driven transcription. This leads to DNA damage and cell death in SS models. SUMOylation assays, SMARCE1 de-SUMOylation validation, ChIP-seq, in vitro and in vivo tumor models with TAK-981 treatment Nature communications Medium 41193430
2024 SS18-SSX1 condensates recognize H2AK119ub histone modification (via the SSX moiety), which accounts for distinctive condensate properties compared to wild-type SS18. SS18-SSX1 condensates hijack wild-type SS18 condensates, relocating SS18 protein to H2AK119ub-marked loci targeted by SS18-SSX1, leading to downregulation of tumor suppressor genes (CAV1, DAB2) normally occupied by SS18. Small-molecule screening, mutant assays, live-cell condensate imaging, histone modification ChIP, gene expression analysis Oncogenesis Medium 39468035
2022 H3K27ac deposition guides rapid relocation of SS18/BAF complexes from pluripotent loci to AP-1 (JUN)-associated loci during JUN-induced pluripotent-to-somatic transition. The direct interaction between SS18/BAFs and JUN-centric protein complexes is undetectable by IP-MS, indicating H3K27ac acts as an indirect signal for BAF redistribution. ChIP-seq, ATAC-seq, IP-MS, BRG1 knockdown, JUN-inducible PST system Cell & bioscience Medium 35710570
2025 SS18-SSX can activate oncogenic transcription independently of BAF complex ATPase activity. Targeted degradation of BAF ATPase subunits (SMARCA4) has modest effects on sarcoma cell viability and does not impede SS18-SSX target gene expression. SS18-SSX promotes transcription by engaging the histone acetyltransferase EP300 independently of BAF, and this activity depends on the C-terminal QPGY-rich domain of SS18. Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumor model, domain-specific SS18-SSX mutants, EP300 Co-IP, pharmacologic EP300/CREBBP degradation with functional readout bioRxivpreprint Medium 41659547
2025 CBX4 (chromobox 4), a canonical polycomb repressive complex member, is a novel interactor of the SS18-SSX fusion oncoprotein, identified by immunoprecipitation-mass spectrometry using a fusion-junction-specific antibody across six synovial sarcoma cell lines. Immunoprecipitation-mass spectrometry using SS18-SSX fusion-junction antibody across 6 SS cell lines, immunohistochemistry on tissue microarray Laboratory investigation Medium 40992545
2022 Proximity ligation assay (PLA) demonstrates physical interaction between SS18-SSX and the BAF complex member BRG1 in synovial sarcoma cells. ChIP with the SS18-SSX fusion-specific antibody confirms SS18-SSX occupancy at target gene promoters (TLE1, BCL2). Proximity ligation assay, chromatin immunoprecipitation with SS18-SSX fusion-junction-specific antibody Applied immunohistochemistry & molecular morphology Medium 35880992
2019 SS18-SSX drives YAP/TAZ-TEAD transcriptional activity via an IGF-II/IGF-IR signaling loop that dysregulates Hippo effectors LATS1 and MOB1. RNAi knockdown of SS18-SSX reduces YAP/TAZ-TEAD transcriptional activity; conversely, SS18-SSX overexpression in mesenchymal stem cells induces aberrant YAP/TAZ-dependent signals. RNAi knockdown, SS18-SSX overexpression in mesenchymal stem cells, luciferase reporter for YAP/TAZ-TEAD, inhibitor treatment in vitro and in vivo xenograft/CAM models Clinical cancer research Medium 30814111
2025 SUMO2 inhibition by TAK-981 reduces global expression levels and chromatin occupancy of the SS18-SSX fusion protein with a concomitant reduction in H2AK119 ubiquitination (H2AK119ub), an epigenetic mark facilitating synovial sarcoma pathogenesis. CRISPR library screening, SUMO2 genetic depletion, TAK-981 pharmacologic inhibition, transcriptomic profiling, ChIP analysis The EMBO journal Medium 40804185

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 378 23540691
2018 The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. Cancer cell 227 29861296
2020 A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. The American journal of surgical pathology 189 32141887
2007 Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 134 17334349
2012 Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer cell 132 22439931
2018 The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer cell 109 29502955
2012 SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PloS one 103 22442726
2008 Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer research 95 18519690
2013 Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways. The Journal of neuroscience : the official journal of the Society for Neuroscience 89 23785148
2006 The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer research 82 17018603
2019 Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion. The American journal of surgical pathology 81 31094920
2013 SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 80 24166495
2020 When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology 74 32559341
2021 A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction. Cancer discovery 46 34078620
2022 Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas. Nature communications 40 35585082
2019 SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 39 30814111
2015 SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. PloS one 37 26571495
2021 SS18 regulates pluripotent-somatic transition through phase separation. Nature communications 36 34215745
2013 The clinical implication of SS18-SSX fusion gene in synovial sarcoma. British journal of cancer 34 24022186
2012 SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 34 22797074
2018 Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion. The Journal of pathology 33 29533464
2014 SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer science 32 24989082
2016 The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. Scientific reports 30 26905812
2015 β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget 30 26259251
2016 Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma. Oncotarget 28 27572315
2010 Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. International journal of oncology 28 20198325
2014 Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clinical orthopaedics and related research 27 23716114
2013 Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma. Pathology international 27 24422953
2012 Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 27 22976541
2021 SS18 Break-Apart Fluorescence In Situ Hybridization is a Practical and Effective Method for Diagnosing Microsecretory Adenocarcinoma of Salivary Glands. Head and neck pathology 25 33394377
2021 Correlating SS18-SSX immunohistochemistry (IHC) with SS18 fluorescent in situ hybridization (FISH) in synovial sarcomas: a study of 36 cases. Virchows Archiv : an international journal of pathology 25 34091760
2008 The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Molecular cancer research : MCR 25 18234968
2008 Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochemical and biophysical research communications 25 18267106
2004 A novel case of synovial sarcoma of the kidney: impact of SS18/SSX analysis of renal hemangiopericytoma-like tumors. Diagnostic molecular pathology : the American journal of surgical pathology, part B 24 15163009
2017 A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. Oral oncology 23 28249647
2001 Mapping and characterization of the mouse and human SS18 genes, two human SS18-like genes and a mouse Ss18 pseudogene. Cytogenetics and cell genetics 23 11435705
2019 Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma. Genes, chromosomes & cancer 22 31595587
2006 Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression. Human molecular genetics 21 16926188
2020 Undifferentiated round cell sarcomas with novel SS18-POU5F1 fusions. Genes, chromosomes & cancer 20 32557980
2004 A novel FISH assay for SS18-SSX fusion type in synovial sarcoma. Laboratory investigation; a journal of technical methods and pathology 20 15208645
2023 Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis. The American journal of surgical pathology 18 37899499
2022 Microsecretory adenocarcinoma of the skin harboring recurrent SS18 fusions: A cutaneous analog to a newly described salivary gland tumor. Journal of cutaneous pathology 18 35690998
2014 Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer science 17 24975049
2008 Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 16 18714179
2024 Advances of SS18-SSX fusion gene in synovial sarcoma: Emerging novel functions and therapeutic potentials. Biochimica et biophysica acta. Reviews on cancer 15 39528099
2017 Synovial sarcoma showing loss of a green signal in SS18 fluorescence in situ hybridization: a clinicopathological and molecular study of 12 cases. Virchows Archiv : an international journal of pathology 15 28761985
2022 Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity. Human pathology 14 36162599
2018 The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia. Biochemical and biophysical research communications 14 29408457
2010 Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. Human pathology 14 20594581
2024 Undifferentiated Round Cell Sarcoma With CRTC1::SS18 Fusion: Expanding Clinicopathologic Features of a Rare Translocation Sarcoma With Prominent Desmoplastic Stroma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 13 38972355
2020 Cooperation between SS18-SSX1 and miR-214 in Synovial Sarcoma Development and Progression. Cancers 13 32019274
2022 Primary renal sarcoma with SS18::POU5F1 gene fusion. Genes, chromosomes & cancer 12 35521683
2021 CRTC1-SS18 Fusion Sarcoma With Aberrant Anaplastic Lymphoma Kinase Expression. International journal of surgical pathology 10 34057377
2007 Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens. Diagnostic molecular pathology : the American journal of surgical pathology, part B 10 17471153
2022 SS18-SSX drives CREB activation in synovial sarcoma. Cellular oncology (Dordrecht, Netherlands) 9 35556229
2022 Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma. Applied immunohistochemistry & molecular morphology : AIMM 9 35880992
2011 Unknown partner for USP6 and unusual SS18 rearrangement detected by fluorescence in situ hybridization in a solid aneurysmal bone cyst. Cancer genetics 9 21536237
2006 Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci. Cytogenetic and genome research 9 16484776
2022 An SS18::NEDD4 cutaneous spindled and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior. Genes, chromosomes & cancer 8 35639915
2024 Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming. bioRxiv : the preprint server for biology 7 38798672
2021 Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report. Frontiers in oncology 7 34249705
2020 MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction. Neoplasia (New York, N.Y.) 7 32559641
2025 Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma. Science advances 6 40267190
2015 Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 6 25959879
2008 The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells. Experimental cell research 6 18835266
2025 Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma. Nature communications 5 41193430
2025 The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma. Nature communications 5 41330912
2024 Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis. Oncogenesis 5 39468035
2023 SS18-SSX Antibody: A Useful Tool to Save Time and Reduce Costs in Synovial Sarcoma Diagnosis. Proposal of a Novel Diagnostic Algorithm. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 5 37357741
2024 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma. Research square 4 38883782
2020 Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review. Surgical case reports 4 32691176
2018 Epigenetic ConFUSION: SS18-SSX Fusion Rewires BAF Complex to Activate Bivalent Genes in Synovial Sarcoma. Cancer cell 4 29894696
2018 Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma. Oncotarget 4 30680066
2017 First cloned human immortalized adipose derived mesenchymal stem-cell line with chimeric SS18-SSX1 gene (SS-iASC). Cancer genetics 4 29025595
2013 Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein. PloS one 4 24130893
2025 SS18::POU5F1-fused sarcoma of the parotid with divergent ganglioneuromatous differentiation-a novel manifestation of a rare tumor. Virchows Archiv : an international journal of pathology 3 40335789
2024 The Potential of the Probiotic Isolate Lactobacillus plantarum SS18-50 to Prevent Colitis in Mice. Food science & nutrition 3 39803293
2023 Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma. Molecular cancer research : MCR 3 36920288
2023 Poorly differentiated biphasic synovial sarcoma of the vulva, displaying SS18::SSX1 fusion and weak to absent (mosaic) INI1/SMARCB1 immunostaining: A rare case with literature review. Indian journal of pathology & microbiology 3 38391333
2022 H3K27ac mediated SS18/BAFs relocation regulates JUN induced pluripotent-somatic transition. Cell & bioscience 3 35710570
2018 Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section. Applied immunohistochemistry & molecular morphology : AIMM 3 27362474
2018 Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature. Journal of stomatology, oral and maxillofacial surgery 3 29325767
2025 SS18-SSX and SSX c-terminus antibodies for identification of specific fusion oncoprotein in mesenchymal neoplasms. Pathology 2 40128131
2025 The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma. Oncology research 2 40296913
2025 Uterine Myxoid Mesenchymal Tumor With a Novel SS18::VEZF1 Gene Fusion, Lacking Worrisome Histological Features. Genes, chromosomes & cancer 2 40878061
2024 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma. bioRxiv : the preprint server for biology 2 38712286
2023 SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients. International journal of surgical pathology 2 36591871
2021 [Expression of SS18-SSX fusion-specific antibody and SSX C-terminal antibody in synovial sarcoma and its diagnostic value]. Zhonghua bing li xue za zhi = Chinese journal of pathology 2 34405607
2021 Expression of TLE1, INI1, β-catenin, Claudin1, CK7, CK19, SS18 and calponin in synovial sarcoma. Indian journal of pathology & microbiology 2 34673590
2009 Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion. PloS one 2 19649286
2025 Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis. The EMBO journal 1 40804185
2024 SS18-SSX Expression and Clinicopathologic Profiles in a Contemporary Cohort of Primary Paratesticular Synovial Sarcoma: A Series of Fourteen Patients. The American journal of surgical pathology 1 39449577
2020 Calcifying synovial sarcoma of the tongue with SS18 rearrangement: a rare variant in a rare location. Oral surgery, oral medicine, oral pathology and oral radiology 1 32981875
2026 BAF complex-independent gene activation by SS18::SSX. bioRxiv : the preprint server for biology 0 41659547
2026 Coexisting SS18::SSX Fusion and BCOR Overexpression: Unmasking a Primary Renal Synovial Sarcoma Amid Diagnostic Pitfalls. International journal of surgical pathology 0 41731718
2026 Case Report: SS18::POU5F1-fused sarcoma with Flexner-Wintersteiner rosettes: a clinicopathological analysis of a rare tumor in the submandibular gland. Frontiers in oncology 0 41971444
2025 Chromobox 4 (CBX4) Is a Novel Interactor of SS18::SSX in Synovial Sarcoma. Laboratory investigation; a journal of technical methods and pathology 0 40992545
2025 SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation. Cells 0 41440042
2024 SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression. Cell biology and toxicology 0 39707021
2023 Synovial sarcoma with ossification and calcification with SS18 immunochemical expression and rearrangement by fluorescent in situ hybridization. Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 0 37879825

Missed literature

Know a paper Affinage missed for SS18? Flag it for the maintainers and the community.

No submissions yet.